

Patrizia Malkomes

(M.D.)

Senior Consultant

Department of Surgery at Ruhr-University Bochum, Knappschaft Kliniken
In der Schornau 23-25, 44892 Bochum

Academic Career

- 2024: **Habilitation:** *“Entwicklung neuer Therapiestrategien in der chirurgischen Onkologie”*, Goethe University Frankfurt
- 2022-2024: Head of Laboratory for Surgical Research, AG Malkomes
- 2019-2024: Program **“Advanced Clinician Scientist”**, funded by the Mildred-Scheel Nachwuchszenrum of the Hospital of the Goethe University Frankfurt
- 2016-2018: **Program “Clinician Scientist”**, funded by Else-Kröner-Fresenius Stiftung
- 2013-2015: Postdoctoral Fellow during the program **“Young Investigator”** from the Medical Faculty of the Goethe Frankfurt
- 2011-2012: Postdoctoral Fellow during the **“Partnership Program”**, Supervision: Prof. Dr. Michael Rieger, Georg-Speyer-Haus, Institute for Biomedical Research, Frankfurt
- 2010 **M.D. thesis:** *“Expression of growth factors and their receptors in benign diseases of the thyroid”*,
Prof. Katharina Holzer, Department of General and Visceral Surgery at the Hospital of the Goethe University, Frankfurt (Magna cum laude)
- 06/2009 License to practice medicine (Examination: very good)
- 2002-2009 **Studies of medicine** at the Goethe University, Frankfurt

Professional career

- Since 2024 **Senior Consultant and Head of “Upper GI Surgery” Section**, Department of Surgery at the University Hospital Bochum Knappschaft Kliniken, GmbH
- 2022-2024 **Senior Consultant** at the Department of General and Visceral Surgery, Hospital of the Goethe University, Frankfurt
- 2019-2022 **Consultant** at the Department of General and Visceral Surgery, Hospital of the Goethe University, Frankfurt
- 2019 **Board Certified Surgeon** in Visceral Surgery
- 2013 and 2016: Parental leave
- Since 2012: **Resident** at the German Organ Transplantation Foundation (DSO)
- 2009-2019: **Resident** at the Department of General and Visceral Surgery, Hospital of the Goethe University, Frankfurt

Publications (Four most important in chronological order):

- 1) Blaheta RA, Han J, Oppermann E, Bechstein WO, Burkhard K, Haferkamp A, Rieger MA, **Malkomes P**. Transglutaminase 2 promotes epithelial-to-mesenchymal transition by regulating the expression of matrix metalloproteinase 7 in colorectal cancer cells via the MEK/ERK signaling pathway. **Biochim Biophys Acta Mol Basis Dis**. 2025 Jan;1871(1):167538. doi: 10.1016/j.bbadis.2024.167538.
- 2) Keyl J, Bucher A, Jungmann F, Hosch R, Ziller A, Armbruster R, **Malkomes P**, Reissig TM, Koitka S, Tzianopoulos I, Keyl P, Kostbade K, Albers D, Markus P, Treckmann J, Nassenstein K, Haubold J, Makowski M, Forsting M, Baba HA, Kasper S, Siveke JT, Nensa F, Schuler M, Kaissis G, Kleesiek

J, Braren R. Prognostic value of deep learning-derived body composition in advanced pancreatic cancer-a retrospective multicenter study. **ESMO Open**. 2024 Jan;9(1):102219. doi: 10.1016/j.esmoop.2023.102219.

- 3) **Malkomes P**, Lunger I, Oppermann E, Lorenz J, Faqar-Zu-Zaman F, Han J, Bothur S, Ziegler P, Bankov K, Wild P, Bechstein WO, Rieger MA. Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target. **Cancer Gene Ther**. 2023 Jul 13. doi: 10.1038/s41417-023-00641-y.
- 4) **Malkomes P**, Lunger I, Oppermann E, Abou-El-Ardat K, Oellerich T, Günther S, Canbulat C, Bothur S, Schnütgen F, Yu W, Wingert S, Haetscher N, Catapano C, Dietz MS, Heilemann M, Kvasnicka HM, Holzer K, Serve H, Bechstein WO, Rieger MA. Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53. **Oncogene**. 2021 Jun; 40(25), 4352-4367.